BeOne Medicines (ONC) Gains Barclays Overweight Rating Ahead of Key 2025 Data Readouts
BeOne Medicines Ltd. (NASDAQ:ONC) ranks among the best biotech stocks to buy. On September 18, Barclays began coverage of BeOne Medicines Ltd.
Beone Medicines Ltd. (ONC)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 8,799,053 | $2,129,986,760 | 20.66% | |
| 2. | Hillhouse Capital Management Lei Zhang | 1,034,306 | $250,374,453 | 8.06% | |
| 3. | Citadel Investment Group Ken Griffin | 537,156 | $130,029,353 | -46% | 0.02% |
| 4. | Siren L.L.C. Raymond Debbane | 509,990 | $123,453,279 | +3% | 6.39% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 467,590 | $113,189,509 | -3% | 0.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $302.06 | 165,529 | $49,999,938.03 | 18,943,802 | 2021-09-10 | Filing | |
| $108.00 | 5,231,900 | $565,045,200.00 | 5,250,491 | 2018-08-02 | Filing | |
| $108.00 | 582,200 | $62,877,600.00 | 600,791 | 2018-08-02 | Filing | |
| $101.00 | 1,645,148 | $166,159,948.00 | 5,121,404 | 2018-01-18 | Filing | |
| $101.00 | 335,050 | $33,840,050.00 | 708,025 | 2018-01-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $351.12 | 4,162 | $1,461,374.76 | 0 | 2025-10-08 | Filing | |
| $350.22 | 4,733 | $1,657,580.37 | 4,162 | 2025-10-08 | Filing | |
| $347.82 | 664 | $230,952.48 | 8,895 | 2025-10-08 | Filing | |
| $350.00 | 1,112 | $389,200.00 | 0 | 2025-10-08 | Filing | |
| $327.78 | 400 | $131,112.00 | 0 | 2025-09-16 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,490 | $5,277,443 | 0.01% | |
| 2. | 2,700 | $919,890 | 0.12% | |
| 3. | 2,371 | $807,800 | 0.02% | |
| 4. | 1,522 | $518,545 | 0.01% | |
| 5. | 1,068 | $363,868 | 0.01% |
News See All
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
Here’s Why BeOne Medicines Ltd. (ONC) Declined in Q2
Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its second quarter 2025 investor letter for the "Baird Chautauqua International and Global...
Citizens JMP Maintains a Buy Rating on BeOne Medicines (ONC)
BeOne Medicines Ltd. (NASDAQ:ONC) is one of the top high growth international stocks to buy right now.
13 High Growth International Stocks to Buy Right Now
On September 12, CNBC reported that according to data released the same day, the UK economy recorded zero growth in July after expanding by 0.4% in June.
BeOne Medicines (ONC) Reports Positive Phase 1/2 Results for Sonrotoclax in MCL
BeOne Medicines Ltd. (NASDAQ:ONC) ranks among the best-performing European stocks to invest in. On August 29, BeOne Medicines Ltd.
9 Best Performing European Stocks to Invest In
With share values reaching their highest points since the global financial crisis, European banks have experienced a boom this year.
BeOne Medicines Ltd. (ONC) Unveils Promising Breast Cancer Therapies at ASCO 2025
At the 2025 American Society of Clinical Oncology (ASCO) meeting, the company presented promising early-phase results for two novel breast cancer therapies.
11 Best Cancer Stocks to Buy Right Now
Cancer remains the second leading cause of death globally, after heart disease.
BeOne Medicines Ltd. (NASDAQ:ONC) Q2 2025 Earnings Call Transcript
Daniel Maller: Hello and welcome. Thanks for joining us today. I'm Dan Miller, Head of Investor Relations at BeOne Medicines.
Hedge Fund Resource Center Billionaire Hedge Funds
